News Feed Opinion Blog Career Insight Dialogues Celebrities Oncolibrary
Positive Societies Drugs Stories History Cancer Center Near Me Cancer Types Immune Oncology Oncologist Near Me
April, 2025
April 2025
M T W T F S S
 123456
78910111213
14151617181920
21222324252627
282930  
Thorvardur Halfdanarson: Cabozantinib in previously treated advanced NETs
Thor Halfdanarson/mayoclinic.org
Sep 19, 2024, 18:53

Thorvardur Halfdanarson: Cabozantinib in previously treated advanced NETs

Thorvardur Halfdanarson, Professor of Oncology at Mayo Clinic School of Medicine, shared a post on X:

“Hot off the press, Alliance CABINET!

Cabozantinib in previously treated (93% had SSA, 60% had PRRT, 72% had everolimus) advanced NETs.

The primary endpoint, PFS, was significantly better in the cabo arm than placebo.”

Phase 3 Trial of Cabozantinib to Treat Advanced Neuroendocrine Tumors

Authors: Jennifer A. Chan, Susan Geyer, Tyler Zemla, Michael V. Knopp, Spencer Behr, Sydney Pulsipher,Fang-Shu Ou, Ph.D., Amylou C. Dueck, Jared Acoba, Ardaman Shergill, Edward M. Wolin, Thorvardur R. Halfdanarson, Bhavana Konda, Nikolaos A. Trikalinos, Bernard Tawfik, Nitya Raj, Shagufta Shaheen, Namrata Vijayvergia, Arvind Dasari, Jonathan R. Strosberg,  Elise C. Kohn, Matthew H. Kulke, Eileen M. O’Reilly and Jeffrey A. Meyerhardt.

 

Thorvardur Halfdanarson: Cabozantinib in previously treated advanced NETs

Source: Thor Halfdanarson/X

Alliance for Clinical Trials in Oncology Amylou C. Dueck Ardaman Shergill Arvind Dasari Bernard Tawfik Bhavana Konda cancer cancer awareness cancer treatment Edward M. Wolin Eileen M. O'Reilly Elise C. Kohn Fang-Shu Ou fight against cancer Global fight against cancer Jared Acoba Jeffrey A Meyerhardt Jennifer A. Chan Jonathan R. Strosberg Matthew H. Kulke Michael V. Knopp Namrata Vijayvergia Nikolaos A. Trikalinos Nitya Raj OncoDaily Oncology Ph.D Shagufta Shaheen Spencer Behr Susan Geyer Sydney Pulsipher Thor Halfdanarson Thorvardur Halfdanarson Tyler Zemla
Special Coverage
Blog
Apr 19, 2025, 17:53
Cancer Nutrition Tips: Pink Africa Foundation Highlights Healing Benefits
Blog
Apr 19, 2025, 17:21
Exploring the integration of patient-reported outcome measures in clinical practice
Blog
Apr 19, 2025, 17:17
Join our Networks and Working Groups to learn, network and grow - SIOP
Blog
Apr 19, 2025, 17:14
Re-irradiation revolution: Maximising technical advances in imaging, biology and dose evaluation at ESTRO 2025
Blog
Apr 19, 2025, 17:02
New whitepaper on navigation services and reimbursement success - Florida Cancer Specialists and Research Institute
Blog
Apr 19, 2025, 17:01
Chiara Mercinelli: Honored to have been selected for the ASCO 2025 Merit Award
Blog
Apr 19, 2025, 16:48
How EveryGrant helps organizations build impactful grant programs - Conquer Cancer, the ASCO Foundation
Blog
Apr 19, 2025, 16:44
Agenus to Reveal Phase 1 HCC Immunotherapy Data at AACR 2025
Blog
Apr 19, 2025, 16:36
Bilal Awad: Knowledge, attitudes, and self-efficacy regarding palliative care among Palestinian nurses in intensive care units
Blog
Apr 19, 2025, 16:23
Toufic Kachaamy: Thrilled to give two talks on cancer ablation at DDW2025
Blog
Apr 19, 2025, 16:23
Elvina Almuradova: Olaparib improved ORR and PFS in BRCA-mutated PSR ovarian cancer, but no OS benefit
Blog
Apr 19, 2025, 16:12
Cristian Massacesi: Visiting our AstraZeneca team in Germany to talk oncology ambitions